AMLX · Amylyx Pharmaceuticals, Inc.
$18.50
+1.05 (+6.02%)
At close · Jul 21
Market Cap
$2.06B
Shares
111.19M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Justin Klee | CEO | $2,719,807 |
| Joshua Cohen | CEO | $2,719,807 |
| Camille Bedrosian | Chief Medical Officer | $1,567,674 |
| James Frates | CFO | $1,375,327 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joshua Cohen | CEO | $6,496,255 |
| Justin Klee | CEO | $6,496,255 |
| James Frates | CFO | $2,540,353 |
| Gina M. Mazzariello | General Counsel | $2,298,996 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joshua Cohen | CEO | $7,418,169 |
| Justin Klee | CEO | $7,418,169 |
| James Frates | CFO | $3,510,377 |
| Margaret Olinger | Chief Commercial Officer | $3,447,150 |
| Gina M. Mazzariello | General Counsel | $3,013,676 |
| Camille Bedrosian | Chief Medical Officer | $2,372,859 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Justin Klee | CEO | $7,178,416 |
| Joshua Cohen | CEO | $7,178,416 |
| Gina M. Mazzariello | General Counsel | $6,113,548 |
| James Frates | CFO | $3,658,945 |
| Margaret Olinger | Chief Commercial Officer | $2,995,817 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James Frates | CFO | $3,255,900 |
| Justin Klee | CEO | $1,424,533 |
| Joshua Cohen | CEO | $1,424,533 |
| Margaret Olinger | Chief Commercial Officer | $863,398 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Justin Klee | CEO | $670,500 |
| Joshua Cohen | CEO | $670,500 |
| Margaret Olinger | Chief Commercial Officer | $515,036 |
Key facts
CIK
1658551
CUSIP
03237H101
13F (30d)
10 filings
10 filers
Visit website
Investor relations